From HemOnc.org - A Hematology Oncology Wiki
Mechanism of action
A recombinant, humanized, bispecific monoclonal antibody that bridges activated factor IX and factor X to restore the function of missing activated factor VIII.
Diseases for which it is used
History of changes in FDA indication
- 11/16/2017: FDA approved "for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors."
Also known as
- Code name: ACE910
- Brand name: Hemlibra